Bone-targeting agents were 2011's top story
Added: Wednesday 1 February 2012
Dr Lee Schwartzberg argues that bone-targeting agents were the most important development of 2011 for supportive car oncology. Because bone is a very common metastatic site for various different types of cancers, bone health is an important research area. He praises the use of denosumab in patients receiving hormonal deprivation therapy (which can lead to bone loss).
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: